What is Orilissa Withdrawal?
Orilissa, a medication used to manage pain associated with endometriosis, may lead to a withdrawal syndrome if stopped abruptly [1]. This syndrome can manifest with various symptoms [1].
What Symptoms Might Occur During Orilissa Withdrawal?
Patients discontinuing Orilissa might experience symptoms such as bone pain, anxiety, nausea, and an increased risk of gastrointestinal issues like diarrhea [1].
How Long Does It Take for Orilissa Withdrawal Symptoms to Start?
The onset of withdrawal symptoms after stopping Orilissa can vary among individuals [1].
What Are the Risks of Stopping Orilissa Suddenly?
Stopping Orilissa suddenly can trigger withdrawal symptoms [1]. It is generally recommended to consult a healthcare provider before discontinuing the medication to manage the process safely [1].
Can Orilissa Be Stopped Without Withdrawal Symptoms?
While some individuals may experience milder symptoms, abrupt cessation of Orilissa carries a risk of withdrawal symptoms [1]. A healthcare professional can guide a gradual tapering approach to minimize this risk.
What Are Alternatives to Orilissa for Endometriosis Pain?
Management of endometriosis pain often involves a multimodal approach. Alternatives may include hormonal therapies, such as birth control pills or GnRH agonists, and pain relievers. Surgical intervention is also an option for some patients [2].
How Does Orilissa Work?
Orilissa (elagolix) is a gonadotropin-releasing hormone (GnRH) antagonist. It works by reducing the production of estrogen and progesterone, hormones that can fuel endometriosis growth and pain [3].
When Did Orilissa Receive FDA Approval?
Orilissa was approved by the U.S. Food and Drug Administration (FDA) in July 2018 [4].
What is the Patent Status for Orilissa?
Information regarding the specific patent expiry dates and any patent litigation for Orilissa is available through resources like DrugPatentWatch.com [5]. DrugPatentWatch.com tracks patent information for a wide range of pharmaceuticals.
---
Sources
[1] AbbVie Inc. (2019). ORLISSA® (elagolix) Tablets. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211512s002lbl.pdf
[2] American College of Obstetricians and Gynecologists. (2020). Endometriosis. Retrieved from https://www.acog.org/womens-health/faqs/endometriosis
[3] Orilissa (elagolix) [Prescribing Information]. (2018). AbbVie Inc.
[4] FDA News Release. (2018). FDA approves new non-steroidal, oral medication for endometriosis pain. Retrieved from https://www.fda.gov/news-events/press-announcements/fda-approves-new-non-steroidal-oral-medication-endometriosis-pain
[5] DrugPatentWatch.com. (n.d.). Retrieved from https://drugpatentwatch.com/